Clinical trials have shown the beneficial effects of SGLT2 inhibitors in patients with type 2 diabetes at high CV risk or established atherosclerotic CV diseases, HF, or chronic kidney disease. The gene discussed is SLC5A2; the disease is chronic kidney disease.